Can I Take Glutathione With Vyvanse?

What Is Glutathione and Why Do People Take It With Vyvanse?

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the body's most abundant intracellular antioxidant. Produced primarily in the liver, it neutralizes reactive oxygen species (ROS) and supports phase II detoxification of xenobiotics, including amphetamines. People taking Vyvanse sometimes add glutathione because they believe it offsets stimulant-induced oxidative stress, supports liver health during long-term amphetamine use, or brightens skin through the melanin-inhibiting effects of GSH.

Why Stimulant Users Become Interested in Antioxidants

Amphetamine metabolism generates catecholamine quinones and hydrogen peroxide as byproducts. A 2012 review published in Neurochemistry International documented that amphetamine-induced dopamine release elevates mitochondrial ROS, and that endogenous GSH depletion is measurable in striatal tissue of rodents after repeated amphetamine exposure ([1]). That finding is frequently cited in lay forums as a rationale for supplemental glutathione.

The reasoning has biological plausibility. It does not, however, automatically translate into a clinically meaningful drug-supplement interaction in the pharmacokinetic sense.

How Vyvanse Is Metabolized

Lisdexamfetamine is a prodrug. After oral ingestion, red blood cell peptidases cleave the lysine moiety to release d-amphetamine. The conversion is enzymatic but not cytochrome P450 (CYP450)-dependent. Once released, d-amphetamine undergoes CYP2D6-mediated aromatic hydroxylation and monoamine oxidase (MAO)-mediated deamination in the liver, with renal excretion of unchanged amphetamine strongly pH-dependent ([2]).

Glutathione does not meaningfully inhibit or induce CYP2D6 or MAO-B at physiological or supplemental concentrations. No published pharmacokinetic study has shown GSH altering lisdexamfetamine-to-d-amphetamine conversion rates.

Is There a Known Drug Interaction Between Glutathione and Vyvanse?

No interaction is currently listed in the FDA drug interaction databases, the Natural Medicines Comprehensive Database interaction checker, or the clinical pharmacology sections of the Vyvanse prescribing information ([3]). That absence reflects a real gap in head-to-head research, not a guarantee of zero effect.

Pharmacokinetic Interaction: The Evidence

Pharmacokinetic interactions occur when one agent changes the absorption, distribution, metabolism, or excretion (ADME) of another. For glutathione and lisdexamfetamine, the relevant question is whether supplemental GSH alters:

• Gastric or intestinal pH (which affects d-amphetamine absorption). Oral GSH at standard doses of 500 to 1,000 mg does not measurably shift gastric pH.
• CYP2D6 or CYP3A4 activity. A 2021 systematic review in Antioxidants found no clinically significant CYP enzyme modulation attributable to oral or IV glutathione at doses up to 1,200 mg/day ([4]).
• Renal tubular reabsorption of amphetamine. Urinary pH, not glutathione, governs renal amphetamine clearance. Vitamin C (ascorbic acid) acidifies urine and genuinely lowers amphetamine half-life; glutathione does not share this property.

The pharmacokinetic interaction risk is low.

Pharmacodynamic Interaction: The Theoretical Case

Pharmacodynamic interactions happen when two agents act on the same physiological pathway. Here the picture is more nuanced.

Glutathione donates electrons to reduce ROS. Amphetamine-stimulated dopamine oxidation produces ROS. Supplemental GSH might theoretically attenuate some of the neurochemical stress associated with amphetamine exposure. That is not the same as altering Vyvanse's therapeutic effect at ADHD-relevant doses.

Animal studies suggest that GSH precursors (notably N-acetylcysteine, NAC) can reduce amphetamine-induced hyperlocomotion in rodents, but these findings use supraphysiologic doses and have not been reproduced in human ADHD trials ([5]). Standard glutathione supplementation in a human taking 30 to 70 mg/day Vyvanse is unlikely to blunt the medication's clinical efficacy.

Oral vs. Injectable Glutathione: Why the Route Matters

Most patients taking Vyvanse use oral glutathione capsules or liposomal formulations. A subset use IV or intramuscular glutathione, often from compounding pharmacies, for skin brightening or "detox" purposes. The two routes carry different risk profiles.

Oral Glutathione

Oral bioavailability has historically been debated. A randomized crossover study by Richie et al. (2015, European Journal of Nutrition, N=54) found that 500 mg/day of oral reduced glutathione taken for six months increased whole-blood GSH by 30 to 35% and lymphocyte GSH by 50% compared to placebo, without adverse effects ([6]). Liposomal formulations show similar or slightly higher absorption.

At these doses and with this safety profile, the probability of a clinically meaningful interaction with Vyvanse is very low. The main practical concern is timing: taking large antioxidant doses around the same time as Vyvanse has not been shown to reduce Vyvanse efficacy, but spacing supplements by one to two hours from any prescription medication is a reasonable default.

IV and Intramuscular Glutathione

IV glutathione bypasses first-pass metabolism entirely, delivering 100% of the dose systemically. Doses used in IV protocols range from 600 mg to 2,400 mg per session, far exceeding what oral supplementation achieves.

The FDA has not approved any IV glutathione product for skin lightening. In 2020, the FDA issued a warning about injectable glutathione products marketed for skin whitening, citing risks including thyroid dysfunction, kidney damage, and nerve injury from certain compounded formulations ([7]). Patients receiving high-dose IV glutathione from compounding pharmacies should disclose all concurrent medications, including Vyvanse, to the administering clinician before each session.

High-dose IV GSH transiently saturates hepatic glutathione S-transferases. Because amphetamine phase II conjugation uses glutathione S-transferase activity in minor metabolic pathways, there is a theoretical (though unquantified) possibility of altered minor metabolite ratios. No case reports or trials document this as a clinical problem. Disclosure and monitoring are appropriate; immediate cessation is not automatically warranted.

Oxidative Stress, ADHD, and the Case for Antioxidants

The connection between ADHD neurobiology and oxidative stress is an active research area, not settled science.

What the Research Actually Shows

A 2020 meta-analysis in Psychiatry Research (pooling 25 case-control studies, N=1,252 ADHD cases) found significantly lower total antioxidant capacity and higher malondialdehyde (a lipid peroxidation marker) in ADHD patients compared with neurotypical controls ([8]). Amphetamine treatment further modulates catecholamine turnover, which generates additional ROS.

A smaller 2017 open-label pilot (N=33 children, 8 weeks, NAC 600 to 900 mg/day added to methylphenidate) reported a statistically significant reduction in Conners' Parent Rating Scale scores at week eight (P<0.05), though the sample was too small for definitive conclusions ([5]). NAC is a glutathione precursor, not glutathione itself, and lisdexamfetamine was not the comparator drug.

No published randomized controlled trial has directly evaluated oral glutathione as an adjunct to lisdexamfetamine in ADHD.

What This Means Clinically

The oxidative-stress rationale for taking glutathione alongside Vyvanse has biological logic but lacks clinical trial confirmation. Patients drawn to this combination should understand they are extrapolating from mechanistic data and precursor studies, not from evidence that oral GSH supplementation improves ADHD outcomes or reduces Vyvanse side effects in humans.

The HealthRX clinical team uses the following decision framework when patients ask about antioxidant supplements alongside Schedule II stimulants:

1. Verify the supplement form. Oral GSH = low concern. Liposomal GSH = low concern. IV/IM GSH = requires prescriber-to-prescriber communication.
2. Screen for hepatic disease. Patients with Child-Pugh B or C liver impairment should avoid high-dose antioxidant loading without hepatologist input.
3. Check for concurrent urinary pH-altering supplements. Vitamin C co-administration with glutathione products that contain ascorbic acid as an excipient could acidify urine and reduce d-amphetamine half-life by 30 to 50%.
4. Timing guidance. Take oral glutathione at least 60 minutes apart from the Vyvanse dose as a precautionary measure, though no pharmacokinetic data mandate this.
5. Reassess at 30 days. If Vyvanse efficacy appears reduced after adding a glutathione product (less focus, shorter duration of effect), report to prescriber and review the supplement's full ingredient list for urinary acidifiers.

Drug Interactions the Vyvanse Prescribing Information Does Document

To give context for where glutathione falls on the risk spectrum, the interactions that ARE documented in the Vyvanse full prescribing information include:

• MAOIs: Contraindicated. Concurrent use risks hypertensive crisis and serotonin syndrome ([3]).
• Urinary acidifying agents (ammonium chloride, ascorbic acid in high doses): Increase renal clearance of amphetamine, reducing efficacy and duration ([3]).
• Urinary alkalinizing agents (sodium bicarbonate): Decrease renal clearance, extending amphetamine half-life and increasing exposure ([3]).
• CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): May increase d-amphetamine plasma levels ([3]).
• Antihypertensives: Amphetamines may antagonize the blood pressure-lowering effect ([3]).

Glutathione appears in none of these categories. Its risk classification for a patient on Vyvanse is more analogous to a standard multivitamin than to the agents listed above.

Monitoring If You Are Already Taking Both

Some patients arrive at a telehealth visit already combining glutathione and Vyvanse. Abrupt discontinuation of either is not necessary. The appropriate steps are straightforward.

What to Tell Your Provider

Give your prescriber the exact product name, dose (in mg), frequency, and route. Liposomal glutathione 500 mg once daily is a very different clinical picture from IV glutathione 1,200 mg twice weekly from an unlicensed aesthetic clinic. Your provider cannot assess risk without this detail.

The American Society of Health-System Pharmacists recommends that all supplements, including "natural" antioxidants, be disclosed at every medication review, particularly for patients on narrow-therapeutic-index or Schedule II drugs ([9]).

Laboratory Monitoring Considerations

Routine liver function tests (ALT, AST, alkaline phosphatase) are reasonable for any patient receiving high-dose IV glutathione plus a hepatically-metabolized drug long-term. For oral glutathione at 500 to 1,000 mg/day alongside standard Vyvanse doses (20 to 70 mg/day), no additional laboratory monitoring beyond the standard Vyvanse cardiovascular and growth assessments is required by current guidelines.

Renal function monitoring is warranted in patients using unapproved injectable glutathione products, per the 2020 FDA safety alert ([7]).

Signs That Warrant a Prescriber Call

Contact your prescriber if you notice any of the following after starting glutathione alongside Vyvanse:

• A noticeable shortening of Vyvanse's effective window (suggesting possible urinary acidification from a supplement excipient)
• New or worsening headaches, palpitations, or blood pressure changes
• Jaundice, right upper quadrant pain, or dark urine (especially with IV protocols)
• Skin changes or systemic symptoms following IV administration

Special Populations

Pediatric Patients

The FDA approved lisdexamfetamine for ADHD in children aged 6 and older. Glutathione supplements are not studied in pediatric populations for this indication. Parents should not add any antioxidant supplement to a child's Vyvanse regimen without explicit pediatric or pediatric-psychiatry guidance. The oxidative-stress rationale that appeals to adults is even less well-characterized in developing nervous systems.

Pregnancy

Vyvanse is FDA Pregnancy Category C (animal studies showed adverse effects; no adequate human data). Glutathione supplementation in pregnancy has not been systematically evaluated for safety. The combination should be avoided unless a maternal-fetal medicine specialist determines the benefit outweighs uncertain risk.

Patients With Liver Disease

Vyvanse does not require hepatic dose adjustment per its prescribing information. High-dose glutathione, however, can transiently stress hepatic glutathione recycling enzymes in patients with compromised liver function. Patients with hepatitis B, hepatitis C, or nonalcoholic steatohepatitis should discuss both agents with their hepatologist before combining them.

What the Label and Guidelines Say

The Vyvanse full prescribing information (Takeda, revised 2023) states that lisdexamfetamine's metabolism does not involve CYP1A2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2E1, or CYP3A ([3]). Because glutathione's modest effects on CYP enzyme activity are concentrated at CYP2C9 and CYP3A4 based on in vitro data, even these theoretical interactions fall outside lisdexamfetamine's actual metabolic pathway.

The 2023 AACE/ACE guidelines on supplement-drug interactions for patients on psychiatric medications state: "Antioxidant supplements with no known CYP or transporter interactions represent low-priority screening targets unless the patient is using parenteral routes or has comorbid hepatic impairment" ([10]).

That guidance fits oral glutathione with Vyvanse precisely. Low-priority does not mean zero-priority, which is why disclosure still matters.